GlaxoSmithKline | GSK - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 6.72B 1.99B 2026-06
Alcon AG USD 297M 16M 2026-03
Almirall EUR 71.55M 41.32M 2026-06
Amgen USD 3.83B 130M 2026-03
argenx SE USD 493M 99M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD -243.8M 758.1M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eli Lilly USD 9.78B 792M 2026-03
Fresenius EUR 713M 139M 2025-12
Fresenius Medical Care EUR 268M 395M 2026-03
Genmab DKK 260M 199M 2025-12
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.6B 312M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
GRIFOLS EUR 249M 26.38M 2026-03
Hikma Pharmaceutical USD 348M 161M 2025-12
Lakefront Biotherapeutics EUR -63.7M 844.26M 2026-03
Lonza CHF 673M 243M 2025-06
Merck EUR 1.05B 572M 2026-03
Merck USD -1.88B 8.12B 2026-03
Novartis USD 4.75B 515M 2026-06
Novo Nordisk DKK 59.62B 27.24B 2026-03
Orion EUR 176.6M 61.8M 2026-06
Pfizer USD 4.99B 340M 2026-03
Philips EUR 610M 308M 2026-06
Recordati EUR 231.11M 47.11M 2026-03
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 2.38B 449M 2026-06
Smith & Nephew USD 440M 50M 2025-12
UCB EUR 1.29B 571M 2025-12